JP2022532801A - がんの治療において使用するための官能基化金カルベンナフトキノン錯体 - Google Patents

がんの治療において使用するための官能基化金カルベンナフトキノン錯体 Download PDF

Info

Publication number
JP2022532801A
JP2022532801A JP2021569297A JP2021569297A JP2022532801A JP 2022532801 A JP2022532801 A JP 2022532801A JP 2021569297 A JP2021569297 A JP 2021569297A JP 2021569297 A JP2021569297 A JP 2021569297A JP 2022532801 A JP2022532801 A JP 2022532801A
Authority
JP
Japan
Prior art keywords
substituted
alkyl
compound according
alkoxy
dialkylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021569297A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532801A5 (https=
Inventor
ジョナサン エル． セスラー
サジャル セン
ジョナサン エフ． アランブーラ
ジェンロン クイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2022532801A publication Critical patent/JP2022532801A/ja
Publication of JP2022532801A5 publication Critical patent/JP2022532801A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/12—Gold compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/10—Silver compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021569297A 2019-05-22 2020-05-22 がんの治療において使用するための官能基化金カルベンナフトキノン錯体 Pending JP2022532801A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962851187P 2019-05-22 2019-05-22
US62/851,187 2019-05-22
PCT/US2020/034415 WO2020237225A1 (en) 2019-05-22 2020-05-22 Functionalized gold carbene naphthoquinone complexes for use in the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2022532801A true JP2022532801A (ja) 2022-07-19
JP2022532801A5 JP2022532801A5 (https=) 2023-06-01

Family

ID=73459479

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021569297A Pending JP2022532801A (ja) 2019-05-22 2020-05-22 がんの治療において使用するための官能基化金カルベンナフトキノン錯体

Country Status (11)

Country Link
US (1) US12577262B2 (https=)
EP (1) EP3972981A4 (https=)
JP (1) JP2022532801A (https=)
KR (1) KR20220024123A (https=)
CN (1) CN114174305A (https=)
AU (1) AU2020279478A1 (https=)
CA (1) CA3140716A1 (https=)
IL (1) IL288176A (https=)
MX (1) MX2021014195A (https=)
SG (1) SG11202112856QA (https=)
WO (1) WO2020237225A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201003483D0 (en) * 2010-03-02 2010-04-14 Univ St Andrews Gold complexes
US8900654B2 (en) * 2011-07-29 2014-12-02 Thin Film Electronics, Inc. Methods of polymerizing silanes and cyclosilanes using N-heterocyclic carbenes, metal complexes having N-heterocyclic carbene ligands, and lanthanide compounds
HUE033704T2 (en) 2012-02-13 2017-12-28 Bristol Myers Squibb Co Enediyne compounds, conjugates thereof, and uses and methods therefor
US20170129911A1 (en) 2015-11-10 2017-05-11 Massachusetts Institute Of Technology Complexes comprising a platinum compound and an immune checkpoint inhibitor and related methods
WO2019006327A1 (en) * 2017-06-30 2019-01-03 Board Of Regents, The University Of Texas System OR-CARBENE COMPLEXES CONTAINING NAPHTOQUINONE AND METHODS OF USE

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DALTON TRANSACTIONS, vol. 46, no. 9, JPN6024026258, 2017, pages 2988 - 2997, ISSN: 0005364834 *
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 85, JPN6024026259, 2014, pages 87 - 94, ISSN: 0005364835 *

Also Published As

Publication number Publication date
EP3972981A4 (en) 2023-05-24
CA3140716A1 (en) 2020-11-26
KR20220024123A (ko) 2022-03-03
EP3972981A1 (en) 2022-03-30
US12577262B2 (en) 2026-03-17
AU2020279478A1 (en) 2021-12-09
CN114174305A (zh) 2022-03-11
WO2020237225A1 (en) 2020-11-26
IL288176A (en) 2022-01-01
MX2021014195A (es) 2022-02-21
SG11202112856QA (en) 2021-12-30
US20220340601A1 (en) 2022-10-27

Similar Documents

Publication Publication Date Title
WO2020156285A1 (zh) 一种苯并吡啶酮杂环化合物及其用途
WO2022007841A1 (zh) 一种egfr抑制剂、其制备方法和在药学上的应用
WO2017092635A1 (zh) 一种蛋白激酶抑制剂及其制备方法和医药用途
JP2021102616A (ja) 白金耐性の克服における使用のためのテキサフィリン−白金（ｉｖ）コンジュゲート及び組成物
CN110981870A (zh) 基于pH和GSH双重响应的β-咔啉-环烯酮衍生物及其用途
TWI342309B (en) Novel fused pyrrolocarbazoles
WO2022199547A1 (zh) 一种7,9-二氢嘌呤衍生物及其制药用途
CN106565760A (zh) 氟硼二吡咯衍生物及其制备方法和在医药上的应用
CN115028648A (zh) 三并环化合物及其药物组合物和应用
CN101624376A (zh) 取代酰肼类化合物及其应用
CN107629077A (zh) 酸敏感的吉非替尼‑氟硼二吡咯衍生物及其制备方法和在医药上的应用
CN113773305A (zh) 一种氨基嘧啶衍生物及其作为egfr酪氨酸激酶抑制剂的应用
CN112010839A (zh) 靶向丝/苏氨酸激酶抑制剂的晶型
CN106749478B (zh) pH敏感的1,4‑二取代酞菁锌配合物及其制备方法和在医药上的应用
JPH11510822A (ja) チロシンキナーゼ抑制剤としての置換テトラリルメチレン−オキシインドール同族体
WO2018086242A1 (zh) pH敏感的轴向取代硅酞菁配合物及其制备方法和在医药上的应用
JP2022532801A (ja) がんの治療において使用するための官能基化金カルベンナフトキノン錯体
WO2017101862A1 (zh) 作为egfr抑制剂的5,8-二氢蝶啶-6,7-二酮衍生物及其应用
US11191835B2 (en) Chlorin-vitamin conjugates
WO2018067551A1 (en) Texaphyrin and antitumor antibiotic conjugates
WO2019056376A1 (zh) 酸敏感的吉非替尼-氟硼二吡咯衍生物及其制备方法和在医药上的应用
WO2019056375A1 (zh) 酸敏感的吉非替尼轴向取代酞菁硅配合物及其制备方法和在医药上的应用
CN107629063A (zh) 酸敏感的酞菁锌‑吉非替尼配合物及其制备方法和在医药上的应用
US11203608B2 (en) Platinum-containing compounds, and related compositions and uses thereof
CN121554409A (zh) 羟丙环胺类双功能化合物及其医药用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230519

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230519

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230807

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240708

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250107